AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06020625 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Diagnostic Test
Description: In order to proceed with molecular characterization, the tumor sample already taken for histological diagnosis will undergo DNA and RNA extraction, which will be analyzed for qualitative and quantitative evaluation. Based on the quantitative data, the method to be used for profiling will be decided.~Multigenic genomic profiling will be performed for each patient on already taken tumor tissue using different panels depending on the quality and quantity of nucleic acids, in particular the following will be used: comprehensive Genome Profiling (CGP, ≥500 genes), if at least 40 ng of material is available; Profiling with identification of actionable mutations by targeted sequencing with panels of size >50 genes, if \<40 ng material available.
Study NCT05701514 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elective surgical resection of CPAM between 6 and 9 months of age
Description: Surgical resection of the CPAM between 6 and 9 months of age
Study NCT05555290 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PT027
Description: When administered PT027, participants will receive 2 actuations of albuterol- budesonide per dose administered as oral inhalations.
Study NCT05555290 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PT007
Description: When administered PT007, participants will receive 2 actuations of albuterol administered as oral inhalations.
Study NCT05863416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Description: Intraoperative dexmedetomidine infusion
Study NCT05863416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine infusion
Description: Intraoperative dexmedetomidine infusion
Study NCT04791072 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Breathing exercise training Use of incentive spirometry Aerobic exercise training Strengthening exercises
Study NCT04791072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Breathing exercise training Use of incentive spirometry Aerobic exercise training Strengthening exercises
Study NCT06162832 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Allograft and rHPDGF-BB
Description: At this intervention the periodontal defect will be treated with allograft and rHPDGF-BB (GEM21)
Study NCT06162832 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Allograft and rHPDGF-BB
Description: At this intervention the periodontal defect will be treated with allograft and rHPDGF-BB (GEM21)
Study NCT06162832 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Allograft and Saline solution
Description: This will be used as the control group
Study NCT06162832 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Allograft and Saline solution
Description: This will be used as the control group
Study NCT04113759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Rehabilitative Therapy
Description: BFR cuffs placed at the proximal thigh, just inferior to the greater trochanter.~Inflation time not to exceed 20 minutes. One BFR session per treatment. BFR exercise dosage: 4 sets of the following repetitions 30, 15, 15, 15, 30 second rest between sets, 1 min rest between exercises.~Progress exercise if pain \<2/10 on VAS and RPE \<5 on 0-10 scale. (Heerey et al), and no break down in form.
Study NCT04113759 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sham BFR Rehabilitative Therapy
Description: The schedule, type of exercises, repetition ranges, and other physical therapy interventions will be the same as the BFR experimental group - however a non-occlusive pressure will be applied with the cuff in the control group.
Study NCT05296668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cuffed ETT (Microcuff®, Halyard Health Inc., Atlanta, GA, USA)
Description: (group C) to receive a cuffed ETT for airway management.
Study NCT05296668 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cuffed ETT (Microcuff®, Halyard Health Inc., Atlanta, GA, USA)
Description: (group C) to receive a cuffed ETT for airway management.
Study NCT05296668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uncuffed ETT group
Description: (group U) to receive an uncuffed ETT for airway management.
Study NCT05296668 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncuffed ETT group
Description: (group U) to receive an uncuffed ETT for airway management.
Study NCT06241898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-1709
Description: Subjects participating in Phase Ia study may continue to receive study treatment as long as they continue to show clinical benefit as judged by the investigator, until disease progression or intolerable toxicity, withdrawal of consent, death, or termination of the study.
Study NCT06496919 — intervention group
Intervention type: DRUG
Intervention: Recombinant Mutant Human Tumor Necrosis Factor
Description: The patients who received rmhTNF intraperitoneal perfusion (intraperitoneal surgical field flushing perfusion or intraperitoneal thermal perfusion chemotherapy)
Study NCT04899739 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echoendoscopy
Description: Peripancreatic lymph nodes and at a distance from the pancreas assessment by endoscopic ultrasound, elastography an doppler to record their anatomical location and characteristics. All lymph nodes suspected of metastatic disease will be marked with sterile black ink.
Study NCT05606172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care Intervention for PTSD (PCIP) Youth aged 6 -11
Description: This treatment ranges from 1-4 sessions which last 50 minutes per session. The first session will cover psychoeducation about PTSD symptoms in children that can be delivered to the parent or both the parent and child. The first session will also teach the parent and child a breathing technique to combat the physiological impact of PTSD in children. The subsequent sessions will be tailored to meet the needs of the child's most distressing PTSD symptom cluster including hyper arousal, negative changes in cognition and mood, avoidance, re-experiencing. Each session contains coping skills that the parent and child can learn together. There is also material for parents to address behavior problems in youth. This treatment will be delivered via telehealth.
Study NCT05606172 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Treatment as Usual
Description: Will receive treatment as usual at local clinic and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
Study NCT05353855 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04687046 — intervention group
Intervention type: DEVICE
Intervention: JUVÉDERM VOLUX®
Description: JUVÉDERM VOLUX® injectable gel
Study NCT06412497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: For patients with EBV IgG seropositivity or EBV PCR positivity on pre-transplant evaluations, Rituximab 375 mg/m2 is given IV once on day -14 (+/-2 day) in the outpatient setting. Pre-medicate 30 minutes prior to rituximab with methylprednisolone (1 mg/kg) IV, acetaminophen 15 mg/kg (maximum 650mg) IV or PO and diphenhydramine 1 mg/kg (maximum 50mg) IV or PO.
Study NCT06412497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit ATG
Description: Rabbit ATG will be administered at doses and days indicated above, infused through a 0.22 micrometer filter over 4-6 hours. Pre-medicate 30 minutes prior to ATG infusion with methylprednisolone 1 mg/kg IV, (max dose = 125 mg), acetaminophen 15 mg/kg dose (max dose = 650 mg) enterally and diphenhydramine 1 mg/kg/dose (max dose = 50 mg) enterally or IV.
Study NCT06412497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 14.5 mg/kg is be given as a 2-hour infusion on day -6. If the patient is obese (actual body weight (ABW) >/= 125% of the ideal body weight (IBW)), cyclophosphamide should be dosed using the adjusted body weight (AdjBW): 0.5(ABW-IBW) + IBW. Uroprotection with MESNA (14.5 mg/kg/day) in IV continuous infusion will be provided per institutional guidelines. Hyperhydration is not required for 14.5 mg/kg cyclophosphamide doses.~Cyclophosphamide will be administered at 50 mg/kg using ABW over 2 hours on days +3 and +4. If the patient is obese (ABW >/= 125% of the ideal body weight (IBW)), cyclophosphamide should be dosed using the adjusted body weight (AdjBW): 0.5(ABW-IBW) + IBW. Uroprotection with MESNA (50 mg/kg/day) in IV continuous infusion as well as hyperhydration will be provided per institutional guidelines.
Study NCT06412497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: For all patients, fludarabine dosing will be model-based using Bayesian methodology IV every 24 hours on days -6 to -3 with a cumulative area under the curve (cAUC) of 20 mg\*hr/L.
Study NCT06412497 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: For patients age >/= 25 years, with myelodysplasia, or clonal hematopoiesis, total body irradiation will be 4 Gy, provided in two fractions on day -1. For all other patients, total body irradiation will be 2 Gy provided in a single fraction on day -1.~Each dose of 2 Gy will be given at a dose rate between 1 and 1.9 Gy/minute prescribed to the midplane of the patient at the level of the umbilicus.
Study NCT06412497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Infusion
Description: On day 0 the cells will be infused per cell source specific institutional guidelines.
Study NCT06412497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Transplant G-CSF
Description: Beginning on day +5, patients will receive G-CSF SQ or IV 5 micrograms/kg once daily until post-nadir ANC > 1500/μL for 3 consecutive days or >3000/μL for 1 day.
Study NCT06468878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Intervention Plus Music Induction
Description: VR exposure for acrophobia with background music.
Study NCT06468878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Intervention With No Music Induction
Description: VR exposure for acrophobia with no background music.
Study NCT04862923 — intervention group
Intervention type: DRUG
Intervention: Oral semaglutide
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to treat the participant with a given product is independent of the decision to include him/her in the study.
Study NCT04124341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefrontal Cortical Stimulation (PCS)
Description: Prior to surgery, subjects will undergo a high resolution structural scan to identify anatomical landmarks for rostral anterior and lateral prefrontal cortex. Following identification of target areas, PCS quad leads will be projected over the anterior and lateral prefrontal cortex. Subjects will be kept in the hospital for a minimum of 72 hours for observation during which the investigators will obtain a high resolution spiral CT scan without contrast to confirm lead placements post-operatively and rule out any intra-cranial bleeds. Patients will receive analgesics which they may continue as an outpatient on as needed basis. During this 2-3 weeks recovery period, the attention to pain control and mood is critical. The research team will contact patients at least twice per week to check on their status.
Study NCT05478135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVIFY Oncology Hub
Description: NAVIFY Oncology Hub is a platform that aggregates and organizes disparate data into an intuitive, longitudinal view of the patient's cancer care journey. The platform is designed to optimize and support oncology workflows and decision-making by providing quick access to the most relevant data in one place, so that providers can make decisions more efficiently and collaborate more seamlessly.
Study NCT06302452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adopting Comprehensive Training for FireArm Safety in Trauma Centers
Description: Firearm access screening, brief firearm safe storage intervention, and referral to community and preventive health resources
Study NCT05231733 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SPX-101
Description: Subjects will receive SPX-101 on Day 1 of the first cycle, and will be evaluated for DLTs in the following 3 weeks. After the first cycle, subjects will continue treatment at dosing intervals as determined by safety and PK results. All patients will continue treatment until disease progression, development of unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at patient discretion (maximum duration: 2 years).
Study NCT06460844 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RTx-015
Description: Intravitreal injection using gene therapy to deliver an optogenetic gene to the eye. Cells in the retina use this Optogenetic gene to make a protein that responds to light.
Study NCT06412497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will begin on day +5 at an initial dose of 0.03 mg/kg/day IV via continuous infusion. Goal trough levels will be 10-15 ug/mL until day +14 posttransplant, then decreased to a goal of 5-10 ng/mL thereafter. In the absence of GvHD, tacrolimus will discontinue at day +180 without a taper.
Study NCT05409066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection
Study NCT05409066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous Infusion
Study NCT05409066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Intravenous Infusion
Study NCT05409066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral Capsules
Study NCT04579523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HCT
Study NCT04579523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10
Description: Given IV
Study NCT04579523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04579523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT04579523 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT04579523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection
Study NCT04579523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspirate
Study NCT05409066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Oral Capsules
Study NCT04579523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT04579523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo chest x-rays
Study NCT05550909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine combination
Description: Tablets containing 50mg/135 mg or 100mg/270 mg of artesunate/amodiaquine will be administered according to weight as per manufacturer guidelines
Study NCT05550909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-amodiaquine combination
Description: Tablets containing 50mg/135 mg or 100mg/270 mg of artesunate/amodiaquine will be administered according to weight as per manufacturer guidelines
Study NCT05550909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine Phosphate
Description: The single dose of 0.25mg/kg PQ will be administered in an aqueous solution, according to a standard operating procedure (SOP) provided by the manufacturer.
Study NCT05550909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Tablets containing 20 mg artemether and 120 mg lumefantrine will be administered according to weight as per manufacturer guidelines
Study NCT05550909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Tablets containing 20 mg artemether and 120 mg lumefantrine will be administered according to weight as per manufacturer guidelines
Study NCT05550909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Description: Tablets containing 153 mg of amodiaquine will be administered according to weight, aiming for a dosage of approximately 10 mg (7.7-15.3mg)/kg/day, given once or twice daily (together with artemether-lumefantrine) for three days.
Study NCT06642207 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CBC
Description: to compare platelet count in Ankylosing Spondylitis patients in treatment with Anti-TNF- α and patients with IL17 Inhibitor
Study NCT05026125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil Injection
Description: Injection of 3 μg/kg (Ideal Body Weight) of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
Study NCT05026125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil Injection plus 30%
Description: Injection of 3 μg/kg (Ideal Body Weight) plus 30% of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
Study NCT06067334 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: full arch implant supported screw retained restoration with conventional impression technique
Description: surgical procedures: Implant installation Prosthetic procedures: Conventional impression fabrication of full arch implant supported screw-retained restoration evaluation: Accuracy, Passive fit
Study NCT06067334 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: full arch implant supported screw retained restoration with conventional digital technique
Description: surgical procedures: Implant installation Prosthetic procedures: Digital impression fabrication of full arch implant-supported screw-retained restoration evaluation: Accuracy, Passive fit
Study NCT06023888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mapping strategy
Description: The ablation strategy was based on the mapping results of periodicity.
Study NCT06023888 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mapping strategy
Description: PVI+ non-PV trigger
Study NCT05823519 — intervention group
Intervention type: DEVICE
Intervention: Endologix Ovation Alto Endograft
Description: Implantation of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms
Study NCT06412497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil (MMF) therapy will begin on day +5. For pediatric service patients dosing of MMF will be 15 mg/kg/dose (max = 1000 mg) three times daily. For adult service patients dosing of MMF will be 15 mg/kg/dose (max = 1500 mg) twice daily. The same dosage is used orally or intravenously. Consider dose modification and/or pharmacokinetic measurements if renal and/or hepatic impairment (GFR\<25 mL/minute corrected). Stop MMF at Day +35 or 7 days after engraftment achieved (ANC>500 x 106 neutrophils/L x 3 days) if later than day +35. If sufficient acute GvHD is observed to require systemic therapy, MMF should be continued for 7 days after initiation of systemic therapy. Afterward, use of MMF is at the discretion of the treating physician.
Study NCT05783479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol
Description: estradiol 0.5 mg in vaginal cream twice daily for 10 days pre-procedure
Study NCT05783479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: hyaluronic acid 5 mg in vaginal gel twice daily for 10 days pre-procedure
Study NCT04812106 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT04958980 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Specific and educational guidelines on care for pathology (diabetes mellitus) according to each profession involved in the research
Description: Physician: Guidance on pathology, sequelae and treatment, as well as guidance on the importance of medical monitoring.~Dental surgeon: guidance on oral health, demonstration of brushing techniques and daily flossing and periodontal changes resulting from diabetes mellitus.~Nurse: Guidance on pathology prioritizing pathophysiology, self-care and skin care and wound prevention (vascular sequelae).~Nutritionist: nutritional guidelines on diabetes mellitus and healthy eating habits.~Physiotherapist: guidance on prevention of falls and injuries and health promotion.~Physical educator: guidance on the importance of practicing physical activities for general health, encouraging self-care and body awareness and demonstrating basic physical activities that can be performed at home.
Study NCT04905602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1905/placebo
Description: Drug: SHR-1905 subcutaneous, single dose~Drug: Placebo subcutaneous, single dose
Study NCT06441981 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: Educational material brochures will be given to 800 respondents. Educational material is provided via WhatsApp chatbot. After being educated, respondents were given a test to determine the increase in understanding of the material.